Antirheumatic agents in covid-19: is IL-6 the right target?

Affiliations

¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
² Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
³ Department of Medical Sciences, Surgery and Neurosciences, Section of Radiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁴ Section of Infectious Diseases, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁵ Department of Medical Biotechnologies, Section of Infectious Diseases, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁶ Section of Pneumology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁷ Department of Medical Sciences, Surgery and Neurosciences, Section of Pneumology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁸ Department of Medical Sciences, Surgery and Neurosciences, Section of Intensive Care, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁹ Department of Medical Biotechnologies, Section of Cardiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
¹⁰ Section of Cardiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
¹¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Rheumatology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

PMID: 32299796
DOI: 10.1136/annrheumdis-2020-217523

Comment

Antirheumatic agents in covid-19: is IL-6 the right target?

Pier Leopoldo Capecchi et al. Ann Rheum Dis. 2021 Jan.

. 2021 Jan;80(1):e2.

doi: 10.1136/annrheumdis-2020-217523. Epub 2020 Apr 16.

Affiliations

¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
² Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
³ Department of Medical Sciences, Surgery and Neurosciences, Section of Radiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁴ Section of Infectious Diseases, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁵ Department of Medical Biotechnologies, Section of Infectious Diseases, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁶ Section of Pneumology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁷ Department of Medical Sciences, Surgery and Neurosciences, Section of Pneumology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁸ Department of Medical Sciences, Surgery and Neurosciences, Section of Intensive Care, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁹ Department of Medical Biotechnologies, Section of Cardiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
¹⁰ Section of Cardiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
¹¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Rheumatology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

PMID: 32299796
DOI: 10.1136/annrheumdis-2020-217523

No abstract available

Keywords: antirheumatic agents; cardiovascular diseases; inflammation; patient care team.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment in

The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.
Monti S, Montecucco C. Monti S, et al. Ann Rheum Dis. 2021 Jan;80(1):e3. doi: 10.1136/annrheumdis-2020-217545. Epub 2020 Apr 27. Ann Rheum Dis. 2021. PMID: 32340978 No abstract available.
Rational use of tocilizumab in COVID-19.
Jain S, Sharma SK. Jain S, et al. Ann Rheum Dis. 2022 Nov;81(11):e213. doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737106 No abstract available.
Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.
Capecchi PL, Lazzerini PE. Capecchi PL, et al. Ann Rheum Dis. 2022 Nov;81(11):e214. doi: 10.1136/annrheumdis-2020-218627. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737112 No abstract available.

Comment on

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Monti S, et al. Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2. Ann Rheum Dis. 2020. PMID: 32241793 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antirheumatic agents in covid-19: is IL-6 the right target?

Affiliations

Antirheumatic agents in covid-19: is IL-6 the right target?

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical